

WHAT IS CLAIMED IS:

1. A method of screening drug candidates comprising:

a) providing a cell that expresses an expression profile gene selected from the group consisting of an expression profile gene set forth in Table 1 or Table 2 or fragment thereof;

b) adding a drug candidate to said cell; and

c) determining the effect of said drug candidate on the expression of said expression profile gene.

2. A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.

3. A method of screening for a bioactive agent capable of binding to a colorectal cancer modulator protein (colorectal cancer modulator protein), wherein said colorectal cancer modulator protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, said method comprising:

a) combining said colorectal cancer modulator protein and a candidate bioactive agent; and

b) determining the binding of said candidate agent to said colorectal cancer modulator protein.

4. A method for screening for a bioactive agent capable of modulating the activity of a colorectal cancer modulator protein, wherein said colorectal cancer modulator protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, said method comprising:

a) combining said colorectal cancer modulator protein and a candidate bioactive agent; and

b) determining the effect of said candidate agent on the bioactivity of said colorectal cancer modulator protein.

5. A method of evaluating the effect of a candidate colorectal cancer drug comprising:

a) administering said drug to a patient;

b) removing a cell sample from said patient; and

c) determining the expression of a gene selected from the group consisting of a nucleic acid of Table 1 or Table 2.

6. A method according to claim 5 further comprising comparing said expression profile to an expression profile of a healthy individual.

7. A method of diagnosing colorectal cancer comprising:

a) determining the expression of one or more genes selected from the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof or a polypeptide encoded thereby in a first tissue type of a first individual; and

b) comparing said expression of said gene(s) from a second normal tissue type from said first individual or a second unaffected individual;

wherein a difference in said expression indicates that the first individual has colorectal cancer.

8. A method for screening for a bioactive agent capable of interfering with the binding of a colorectal cancer modulator protein (colorectal cancer modulator protein) or a fragment thereof and an antibody which binds to said colorectal cancer modulator protein or fragment thereof, said method comprising:

a) combining a colorectal cancer modulator protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said colorectal cancer modulator protein or fragment thereof; and

b) determining the binding of said colorectal cancer modulator protein or fragment thereof and said antibody.

1 9. A method for inhibiting the activity of a colorectal cancer modulator  
2 protein (colorectal cancer modulator protein), wherein said colorectal cancer modulator  
3 protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of  
4 Table 1 or Table 2 or a fragment thereof, said method comprising binding an inhibitor to said  
5 colorectal cancer modulator protein.

1 10. A method according to claim 9 wherein said inhibitor is an antibody.

1 11. A method of treating colorectal cancer comprising administering to a  
2 patient an inhibitor of a colorectal cancer modulator protein, wherein said colorectal cancer  
3 modulator protein is encoded by a nucleic acid selected from the group consisting of a  
4 nucleic acid of Table 1 or Table 2 or a fragment thereof.

1 12. A method according to claim 11 wherein said inhibitor is an antibody.

1 13. A method of neutralizing the effect of a colorectal cancer modulator  
2 protein, or a fragment thereof, comprising contacting an agent specific for said protein with  
3 said protein in an amount sufficient to effect neutralization.

1 14. A method for localizing a therapeutic moiety to colorectal cancer tissue  
2 comprising exposing said tissue to an antibody to a colorectal cancer modulator protein or  
3 fragment thereof conjugated to said therapeutic moiety.

1 15. The method of Claim 14, wherein said therapeutic moiety is a cytotoxic  
2 agent.

1 16. The method of Claim 14, wherein said therapeutic moiety is a  
2 radioisotope.

1 17. A method for inhibiting colorectal cancer in a cell, wherein said method  
2 comprises administering to a cell a composition comprising antisense molecules to a nucleic  
3 acid of Table 1 or Table 2.

1 18. An antibody which specifically binds to a protein encoded by a nucleic  
2 acid of Table 1 or Table 2 or a fragment thereof.

1 19. The antibody of Claim 18, wherein said antibody is a monoclonal  
2 antibody.

1 20. The antibody of Claim 18, wherein said antibody is a humanized  
2 antibody.

1 21. The antibody of Claim 18, wherein said antibody is an antibody fragment.

1 22. A biochip comprising one or more nucleic acid segments selected from  
2 the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, wherein  
3 said biochip comprises fewer than 1000 nucleic acid probes.

1 23. A nucleic acid having a sequence at least 95% homologous to a sequence  
2 of a nucleic acid of Table 1 or Table 2 or its complement.

1 24. A nucleic acid which hybridizes under high stringency to a nucleic acid of  
2 Table 1 or Table 2 or its complement.

1 25. A polypeptide encoded by the nucleic acid of Claim 23 or 24.

1 26. A method of eliciting an immune response in an individual, said method  
2 comprising administering to said individual a composition comprising the polypeptide of  
3 Claim 25 or a fragment thereof.

1 27. A method of eliciting an immune response in an individual, said method  
2 comprising administering to said individual a composition comprising a nucleic acid  
3 comprising a sequence of a nucleic acid of Table 1 or Table 2 or a fragment thereof.

1 28. A method of determining the prognosis of an individual with colorectal  
2 cancer comprising:

3 a) determining the expression of one or more genes selected from the group  
4 consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof in a first tissue type of  
5 a first individual; and

6 b) comparing said expression of said gene(s) from a second normal tissue type  
7 from said first individual or a second unaffected individual;

